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Dear Dr. Becker, 
We thank you for the opportunity to resubmit our manuscript. Please find below the Reviewer’s 
comments from our submission to Journal of Thrombosis and Thrombolysis. We have included 
point-by-point responses to each comment and the corresponding changes made to the main text. 
In addition, changes to the main text can be found tracked in the manuscript. We have made 
substantial revisions in response to the Reviewer’s critiques and feel that the revised manuscript 
is greatly improved.   
 
Reviewer 1 
1. Recurrent VTE was only studied for first 3 months duration and follow up data was 
only available for 56 of the 101 post arthroscopy so conclusions cannot be made 
accurately about recurrence. It would be helpful to know how many arthroscopies 
were performed as part of the registry and out of that 101 patients had VTE- this 
would give the problem perspective It would be helpful if absolute numbers were 
available and not detailed as "per 100 patient years" 
 
We thank the reviewer for the opportunity to clarify. All patients in RIETE must have at 
least 90 days follow-up. Thus, 3 months of follow-up was available for all patients (101 
post arthroscopy VTE and 19,218 unprovoked VTE). In fact, median follow up was 201-
311 days in the various groups. Perhaps the reviewer is referring to follow-up after 
anticoagulation was stopped when they are referring to 56 patients? These patients were 
compared with 61 post bone-fracture patients and with 6,410 patients with unprovoked 
VTE for whom this long-term follow-up was available (table 5). However, indeed, 
regarding what happens after anticoagulation was stopped, we agree with the reviewer 
that conclusions cannot be made accurately. We have tried to address this matter in the 
discussion, paragraph 1: 
 
“While recurrent VTE did occur once anticoagulation was stopped, we could not identify 
differences in event rates in comparison to patients with a clearly provoked or 
Response to Reviewer Comments
unprovoked VTE. However, drawing firm conclusions may not be possible given our 
small sample size.” 
 
And, discussion, paragraph 2: 
“While firm conclusions cannot be drawn, some patients did have recurrent VTE once 
anticoagulation was stopped.” 
 
Regarding the reviewer’s second comment - Unfortunately, we do not have the data 
regarding the overall number of patients who underwent arthroscopy, because entry into 
the RIETE registry occurs at the time of the venous thromboembolic event. Thus, the 
denominator is unknown to us.  
 
Regarding the reviewer’s comment about data presentation – we provided data per 100 
patient years in order to standardize across different follow-up periods in the different 
groups. Thus, respectfully, absolute number may actually present a wrong impression. 
 
Reviewer 2 
1. The rationale for including a third group (post fracture) needs to be explained; 
seems to be more useful for a separate analysis (Manuscript), provided that 
additional and detailed data are available. A comparison with total knee 
replacement would have been more promising. 
 
We thank the reviewer for the opportunity to clarify. We have chosen to include two 
comparisons: one to patients who developed an unprovoked VTE and another to patients 
who developed VTE post bone-fracture. Patients post bone-fracture were chosen as they 
represent a group who have a provoked event. In the discussion, paragraph 2 we 
attempt to clarify: 
 
“In order to provide context, we compared post-arthroscopy VTE to two separate cohorts: 
those with clearly unprovoked VTE and those with provoked VTE after bone-fracture”. 
 
We agree with the reviewer that there is much more to report regarding these patients. 
 
Regarding the reviewer’s second comment - While the RIETE registry does include 
patients with VTE post total knee replacement, we opted to choose a different 
representation for provoked VTE in order to avoid confusion, as knee replacement is very 
different than knee arthroscopy. 
 
2. As there are substantial differences in baseline patient characteristics, and in view 
of the very large number of unprovoked VTE in RIETE, attempts could have been 
undertaken (or at least discussed) to match patients or to use propensity scores, or 
similar. 
 
Thank you for this comment. We agree that, in general, adjusted, or matched, analyses in 
comparative observational studies can sometimes provide important insights.  However, 
there are several specific flaws to performing adjusted or propensity matched analyses 
with the current study.   
    
Because of the modest sample size and low event rates, traditional methods of adjustment 
are unfortunately invalid (traditional rule of thumb is to include one covariate for 
adjustment for every 10 events in the study population). Regarding propensity matching, 
despite reporting on the largest group of patients with post-arthroscopy VTE in the 
literature, the overall sample size is still modest and the confidence intervals surrounding 
our observed event rates are very wide.  Thus, unfortunately, only minimal additional 
information is likely to be provided apart from simply selecting and shrinking the 
comparator population. 
 
Given all of the above issues, we aimed to compare our post-arthroscopy patients to a 
“naturally occurring” similar population.  As noted above, this is why we also included 
the analysis of post bone-fracture patients.  While not a true adjusted analysis, this does 
provide additional context to the reader regarding the findings in our post-arthroscopy 
population.   
 
 
3. In the discussion section the authors state that they could not identify differences in 
the event rates between provoked and unprovoked VTE. This could be explained by 
the small number of patients undergoing knee arthroscopy. 
 
Thank you. We agree with the reviewer. We made the following changes to the 
discussion, paragraph 1 to add clarity: 
 
“While recurrent VTE did occur once anticoagulation was stopped, we could not identify 
differences in event rates in comparison to patients with a clearly provoked or 
unprovoked VTE. However, drawing firm conclusions may not be possible given our 
small sample size.” 
 
4. The percentage of DOAC use was twice as high in the arthroscopy group compared 
to unprovoked patients. Here, a discussion on the enrollment time periods of the two 
groups (and availability of DOACs) is missing 
 
Thank you for this comment. Direct oral anticoagulants (DOAC) were introduced to the 
European market in 2013. Patients included in the current study were recruited between 
2009 and 2017. Patients across the various groups were recruited over a similar period. 
Thus, the difference in DOAC prescription reflects more of a practice difference than a 
difference in the period of recruitment.  
 
We added a clarification in the discussion, paragraph 2: 
 
“While more patients in the post-arthroscopy group received a DOAC, it should be noted 
that this did not reflect differences in availability as most patients were recruited over 
similar timeframes.” 
 
5. The written English has to be reviewed and corrected (spelling errors and wording) 
 
Thank you for the opportunity to improve our manuscript. We have scrutinized our re-
submission and did our best to minimize such errors. We wholeheartedly welcome any 
further suggestions. 
 
6. Table 1 should show the odds ratio (last column) compared with unprovoked VTE 
 
We apologize if there was any issue with the format that reached the reviewer or if we are 
misunderstanding the reviewer’s request. Table 1 indeed has two comparisons: 
Arthroscopy vs. Provoked (the column before last) and Arthroscopy vs. Unprovoked (last 
column). 
 
7. Table 2: high rate of syncope in PE patients should be mentioned 
 
Thank you for pointing this out. We have now highlighted the high rate of syncope in the 
discussion, paragraph 1: 
 
“Nonetheless, in absolute terms the incidence of syncope was still high.” 
 
8. P9: However, this practice may over-estimate the incidence of DVT and may 
result in treatment-related complications. 
 
Thank you again for the opportunity to avoid mistakes. We have revised according to the 
reviewer’s recommendation. 
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Abstract: 
Background 
Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of 
post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient 
outcomes have not been described. 
Methods 
Patients from the “Registro Informatizado Enfermedad TromboEmbolica” (RIETE) who had 
confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, 
and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, 
treatment and outcomes including recurrent VTE, bleeds or death were compared. 
Results 
A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE 
were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P<0.0001) and had 
less history of VTE [5.9% vs. 20%, OR 0.26 (0.11-0.59)].  Among patients with isolated DVT, 
there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06-
0.19)]. Treatment duration was shorter in the post-arthroscopy group (174±140 vs. 311±340 
days, P<0.0001) and more often with DOAC [OR 3.67 (1.95-6.89)]. Recurrent VTE occurred in 
6.18 (1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years [HR 0.52 (0.16-1.26)] after 
treatment in the post-arthroscopy and unprovoked groups, respectively. Recurrent VTE 
occurred in 5.17 (1.31-14.1) per 100 patient years in a separate post bone-fracture group (n = 
147), also not statistically different than the post-arthroscopy recurrence rate. 
Conclusions 
After anticoagulation is stoppedcessation, some patients post-knee arthroscopy develop VTE. 
While our small sample size precludes drawing firm conclusions, this signal should warrant 
further research into the optimal treatment duration for these patients, as some patients may 
be at increased risk for long-term recurrence. 
Key Points: 
 Treatment patterns for patients with post-arthroscopy VTE defer thandiffer from those for 
patients with unprovoked VTE 
 Bleeding or thrombotic complications were uncommon during anticoagulation 
 Once anticoagulation is stopped, recurrent VTE occurs in some patients with post-
arthroscopy VTE 
 Future research should be aimed at identifying which patients with post-arthroscopy VTE 
should be treated with long-term anticoagulation 
  
Introduction: 
Knee arthroscopy is usually an elective procedure, performed in relatively young patients, often 
without thromboprophylaxis1. Importantly, these procedures are common; 4 million knee 
arthroscopies are performed annually, typically in the outpatient setting2, 3. After the procedure 
is done, patients often ambulate on their other leg and are fully ambulatory within a few 
weeks. However, despite short procedural duration and early ambulation, proximal deep vein 
thrombosis (DVT)4, 5 and pulmonary embolism (PE) may occur 6-13 with fatal PE cases reported14-
16.  Risk factors for developing venous thromboembolic events (VTE) after these procedures and 
analysis of prevention methods have been published 1, 5, 17-23.  However, treatment patterns 
have not been systematically reported and data regarding patient outcomes are variable3, 18, 19.  
We therefore sought to describe patient characteristics, treatment patterns and outcomes in 
patients who developed VTE after knee arthroscopy in the “Registro Informatizado Enfermedad 
TromboEmbolica” (RIETE) 24. Furthermore, we compared these to patients who developed 
either provoked, post bone- fracture, or unprovoked VTE within the registry. 
 
Methods: 
RIETE is a multi-center, multi-national, ongoing prospective registry of confirmed acute VTE that 
has been populated since March 2001 24.  RIETE is registered at Clinicaltrials.gov (NCT: 
02832245).  As of June 2017, over 72,000 patients have been enrolled to the registry, from 179 
centers around the world. Importantly, to study the outcomes of patients in real-world practice, 
RIETE does not mandate specific treatment protocols and treatment is at the discretion of 
attending physicians at the participating sites. Only patients with at least 3 months of follow-up 
are included. Data quality is constantly monitored by a contract research organization (CRO). All 
patients provide oral consent to their participation in the registry, according to the 
requirements of the Ethics Committee within each participating hospital. 
As noted, only objectively confirmed VTE (ultrasonography or venography for DVT, pulmonary 
angiography or helical computed tomography scan for PE) are included into the registry.  
Participating centers have local Institutional Review Board approval with patients providing 
informed consent for registry enrollment.   
VTE Groups 
Patients who developed VTE between February 2009 and December 2017 within 60 days of 
knee arthroscopy were compared to: 1) patients with unprovoked VTE; and 2) patients with 
provoked VTE post bone -fracture. Unprovoked VTE were defined as lacking transient risk 
factors including recent immobilization >4 days, recent surgery, estrogen use, pregnancy or 
puerperium, and recent travel. Post bone fracture VTE was defined as occurring within 60 days 
of a fracture. 
Variables 
For each patient, the following information was obtained: demographics, past medical history, 
history of prior thrombosis and known thrombophilia; signs, symptoms and laboratory data at 
presentation; treatment including anticoagulation use and type and whether thrombolysis or 
an inferior vena cava filter were offered; and outcomes during the first 3 months including VTE 
recurrence, bleeding and mortality. 
Outcomes 
Major bleeding was defined as occurring in a critical site (retroperitoneal, spinal, or 
intracranial), bleeding requiring transfusion of 2 or more units of packed red blood cells, or fatal 
bleeding 25.  Fatal PE was defined as any death occurring within 10 days of confirmed PE 
without an alternative explanation.  
Recurrent DVT was defined as a new episode of symptomatic and objectively confirmed 
ipsilateral or contralateral DVT. Proximal DVT was defined as occurring in the popliteal vein or 
in a more proximal vein. 
Statistical analysis  
Mann-Whitney test and Student t-test were used to compare continuous variables, and 
categorical variables were compared by the Fisher exact test. Odds ratios (ORs) with 95% 
confidence intervals (CIs) were calculated, and a two tailed P value of .05 was considered 
statistically significant. All reported analyses were unadjusted due to the lack of clinical 
granularity necessary for true adjustment for confounders in the examined clinical scenarios.  




A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE 
were identified.  
Post-arthroscopy patients were younger (49.5 vs. 66 years, P<0.0001), more often male [68% 
vs. 55%, OR 1.77 (1.16-2.69)] and had less history of DVT or PE [5.9% vs. 20%, OR 0.26 (0.11-
0.59)] compared to patients with unprovoked VTE, respectively (Table 1). Also, post-
arthroscopy patients had a lower incidence of chronic diseases such as diabetes [OR 0.06 (0.01-
0.45)], hypertension [OR 0.32 (0.20-0.50)] and chronic lung disease [OR 0.23 (0.07-0.72)] 
compared to patients with unprovoked VTE.  One average VTE occurred within 22.3±17.1 days 
of surgery; 71% of patients with VTE after arthroscopy had received pharmacologic prophylaxis, 
for an average of 12.1±7.9 days. There was no difference in the rate of known thrombophilia 
between groups (2.0% vs. 3.4%).  
About half of the patients in both groups presented with PE (49% and 57%, for the post-
arthroscopy and unprovoked groups, respectively). Among patients with isolated PE, a minority 
of patients in both groups presented with syncope (18% and 15%) or hypotension (4.1% and 
2.4%) or syncope (18% and 15%). Among patients with isolated DVT, there were fewer proximal 
DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06-0.19)]. Otherwise, presentation 
was similar between groups (Table 2). 
Nearly all patients in each group were treated with anticoagulation initially.  Treatment 
duration was shorter in the post-arthroscopy group (173.8±140 days vs. 311.1±340.3 days, 
P<0.0001) and more often with direct oral anticoagulants (DOAC) initially [OR 3.67 (1.95-6.89)], 
and at 3 months [OR 2.67 (1.71-4.18)] (Table 3).  
During treatment with anticoagulation, recurrent VTE occurred in 1.97 (0.10-9.73) and 2.33 
(2.11-2.58) per 100 patient years in the post-arthroscopy and unprovoked groups, respectively 
(Table 4). There were no major bleeds in the post-arthroscopy group and there were 2.31 (2.09-
2.56) per 100 patient years in the unprovoked group.  
Follow-up was available for 56 and 6,410 patients, in the post-arthroscopy and unprovoked 
groups, respectively (Table 5). After treatment was stopped, recurrent VTE occurred in 6.18 
(1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years in the post-arthroscopy and in the 
unprovoked groups, respectively HR 0.52 (0.16-1.26). 
Comparison to Patients with Post-Bone Fracture VTE 
There were 147 patients with post bone-fracture VTE. These patients were older (55.4 vs. 49.5 
years, P<0.01), and more were diabetic (6.8% vs. 1%, P<0.05) compared to patients with post-
arthroscopy VTE. O, but otherwise baseline characteristics and presentation were quite similar. 
Treatment patterns were also similar, though fewer patients in the post bone-fracture group 
received DOAC (15% vs. 26%, P<0.05). The mean duration of therapy post bone-fracture was 
215.3±258.5 days. During treatment with anticoagulation mortality occurred in 7.3 (2.96-15.2) 
per 100 patient years in the post bone-fracture group, while none of the patient in the post-
arthroscopy group had died (P<0.05). Otherwise, outcomes during treatment with 
anticoagulation and after anticoagulation was stopped were similar between patients with 
post-fracture and post-arthroscopy VTEin both groups. 
Discussion: 
In this first systematic analysis of post knee-arthroscopy VTE, most patients had a benign 
presentation including distal DVT or low-risk PE. Nonetheless, in absolute terms the incidence 
of syncope was still high. Treatment typically included anticoagulation and adverse events while 
still being treated during treatment were uncommon. While recurrent VTE did occur once 
anticoagulation was stopped, we could not identify differences in event rates when 
comparingin comparison to patients with a clearly provoked or unprovoked VTE. However, 
drawing firm conclusions may not be possible given our small sample size.  
Descriptions of post-arthroscopy VTE treatment and outcomes are lacking in the literature. 
Several case-reports have reported fatal PE post knee-arthroscopy15, 16. In a retrospective series 
of 102 patients undergoing knee arthroscopy, 8 developed calf-DVT and at a median of 118 
days 50% had auto-lysed, while 1 had propagated to the popliteal vein1. In the Efficacy of 
Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA) study 120 patients 
undergoing knee-arthroscopy received prophylaxis with rivaroxaban and were compared to 119 
patients who received placebo 19. While the study reported outcomes for all patients, 7 patients 
in the placebo arm developed proximal (n=1) or distal (n=6) DVT while 1 patient in the study 
arm developed distal DVT (P=0.03). Treatment was not reported, however none of the patients 
developed PE or died. Similarly, in the largest study to-date where 1327 patients undergoing 
knee-arthroscopy were randomized to receive low molecular weight heparin or placebo for 
thromboprophylaxis, at 3 months the incidence of VTE was 0.6% in the treatment arm and 0.4% 
in the control arm and while treatment was not detailed, no deaths were noted 3. In contrast, 
the current study included only patients who have already sustained a VTE. We report 
management and outcomes.  In order to provide context, we compared post-arthroscopy VTE 
twiceto two separate cohorts: once to those with clearly unprovoked VTE and once to clearly 
those with provoked VTE after bone-fracture. On average, treatment was longer than 6 
months; more than the typical duration of therapy for provoked events26.  While more patients 
in the post-arthroscopy group received a DOAC, it should be noted that this did not reflect 
differences in availability as most patients were recruited over similar timeframes. During the 
course of anticoagulation, there were no differences in the rate of patients developing who 
developed VTE recurrences between patients with post-arthroscopy and either comparison 
group.  While firm conclusions cannot be drawn, Strikingly, some patients did have recurrent 
VTE once anticoagulation was stopped. In absolute terms the recurrence rate was lower than in 
the unprovoked group, however not in a statistically significant manner. But, recurrent events 
were also noted in patients with post-fracture VTE. This is in contrast to published recurrence 
rates for provoked VTE27.  
Strengths of the current study include the detailed description of treatment and outcomes 
during and after anticoagulation. However, our study has limitations. As there were very few 
outcomes in the post-arthroscopy group, we cannot comment about the association of baseline 
characteristics and outcomes.  We could not report on specific procedural data; however 
increased procedural risk was demonstrated across all indications of knee arthroscopy10. 
Finally, we only reported symptomatic events. Proactive surveillance may detect patients with 
asymptomatic DVT1, 4, 19. However, this practice may over-estimate the incidence of DVT3, 5 and 
may result in treatment-related complications14. Furthermore, by reporting only symptomatic 
events our results reflect clinical practice3, 21, 28.  
Conclusions: 
In this largest study to date examining post-knee arthroscopy VTE treatment and outcomes, 
there were few thrombotic complications during anticoagulation. Recurrent VTE did occur in 
some patients afteronce anticoagulation was stoppedcessation. Our small sample size and low 
event rate preclude drawing strong conclusions, however this signal should warrant further 
investigation into the optimal treatment duration for these patients as long-term prevention 
may be warranted for some. 
  







P Value / Odds 
ratio (95% CI) 
Arthroscopy vs. 
fracture 
P Value / Odds 
ratio (95% CI) 
Arthroscopy vs. 
unprovoked 
Patients, N 101 147 19,218   
Age  49.5±13.1 55.4±18.8† 66±16.8‡ 0.004 0.000 
Male sex  69 (68%) 79 (54%)* 10,563 (55%)† 1.86 (1.09-3.15) 1.77 (1.16-2.69) 
Body weight(Kg/m2±SD) 27.6±4.8 27.9±4.3 28.7±5.5 0.627 0.083 
BMI 27.6±4.8 27.9±4.3 28.7±5.5 0.627 0.083 
Chronic lung disease  3 (3.0%) 5 (3.4%) 2,270 (12%)† 0.87 (0.20-3.72) 0.23 (0.07-0.72) 
Congestive heart failure  3 (3.0%) 13 (8.8%) 1,258 (6.5%) 0.32 (0.09-1.14) 0.44 (0.14-1.38) 
Diabetes  1 (0.99%) 10 (6.8%)* 2,654 (14%)‡ 0.14 (0.02-1.09) 0.06 (0.01-0.45) 
Hypertension  23 (23%) 40 (27%) 9,268 (48%)‡ 0.79 (0.44-1.42) 0.32 (0.20-0.50) 
Prior myocardial infarction  4 (4.0%) 8 (5.4%) 1,262 (6.6%) 0.72 (0.21-2.45) 0.59 (0.22-1.60) 
Prior ischemic stroke  2 (2.0%) 1 (0.68%) 1,069 (5.6%) 2.95 (0.26-32.97) 0.34 (0.08-1.39) 
Recent major bleeding  0 4 (2.7%) 183 (0.95%) - - 
Active cancer  1 (0.99%) 6 (4.1%) 0 0.24 (0.03-1.98) - 
History of DVT or PE  6 (5.9%) 6 (4.1%) 3,756 (20%)‡ 1.48 (0.46-4.74) 0.26 (0.11-0.59) 
Pregnancy  0 0 0 - - 
Hormone use  6 (5.9%) 7 (4.8%) 0 1.26 (0.41-3.88) - 
Antiphospholipid syndrome  1 (0.99%) 2 (1.4%) 433 (2.3%) 0.73 (0.06-8.10) 0.43 (0.06-3.12) 
Known thrombophilia  2 (2.0%) 1 (0.68%) 645 (3.4%) 2.95 (0.26-32.97) 0.58 (0.14-2.36) 
Thromboprophylaxis  72 (71%) 123 (84%)* 0 0.48 (0.26-0.90) - 
 LMWH 70 (69%) 114 (78%) 0 0.65 (0.37-1.16) - 
 UFH 0 0 0 - 0 
 DOAC 0 0 0 - 0 
 Others 1 (0.99%) 0 0 -  
 Unspecified 1 (0.99%) 0 0 -  
 
Duration (mean days 
±SD) 
12.1±7.9 23±14.8‡ - 0.000 - 
 
Duration (median days, 
IQR) 
10 (7-14) 21 (10-30) - - - 
BMI – Body mass index, CI – Confidence interval, DVT – Deep vein thrombosis, PE – Pulmonary embolism. *p <0.05; †p <0.01; ‡p 
<0.001.   
 
  
Table 2: Presenting Signs, Symptoms in Patients Presenting with Post-Knee Arthroscopy and Unprovoked Venous 
Thromboembolism 




P Value / Odds 
ratio (95% CI) 
P Value / Odds 
ratio (95% CI) 
All patients, N 101 147 19,218   
Initial VTE presentation,      
Pulmonary embolism 49 (49%) 83 (56%) 10,959 (57%) 0.73 (0.44-1.21) 0.71 (0.48-1.05) 
In patients with PE 49 83 10,959   
Cough 8 (16%) 14 (17%) 2,422 (22%) 0.96 (0.37-2.49) 0.69 (0.32-1.47) 
Dyspnea 34 (69%) 65 (78%) 8,791 (80%) 0.63 (0.28-1.40) 0.56 (0.30-1.03) 
Chest pain 34 (69%) 60 (72%) 5,168 (47%)† 0.87 (0.40-1.89) 2.54 (1.38-4.67) 
Syncope 9 (18%) 6 (7.2%) 1,606 (15%) 2.89 (0.96-8.69) 1.31 (0.63-2.71) 
Heart rate >110 mm Hg 7 (15%) 27 (34%)* 1,835 (17%) 0.35 (0.14-0.88) 0.86 (0.38-1.92) 
SBP levels <90 mm Hg 2 (4.1%) 0 266 (2.4%) - 1.71 (0.41-7.08) 
Sat O2 levels <90% (N=5,928) 5 (21%) 10 (21%) 1,600 (27%) 0.97 (0.29-3.26) 0.71 (0.26-1.90) 
In patients with only DVT 52 64 8,259   
Swollen limb 47 (90%) 55 (86%) 7,445 (90%) 1.54 (0.48-4.91) 1.03 (0.41-2.59) 
Upper limb 1 (2.5%) 2 (4.9%) 656 (11%) 0.50 (0.04-5.74) 0.20 (0.03-1.44) 
   secondary to catheter 1 (100%) 0 109 (17%) 0.333 0.167 
Lower limb 51 (98%) 62 (97%) 7,679 (95%) 1.65 (0.14-18.67) 2.54 (0.35-18.46) 
   Proximal 20 (40%) 41 (66%)† 6,490 (86%)‡ 0.34 (0.16-0.74) 0.11 (0.06-0.19) 
CI – Confidence interval, DVT – Deep vein thrombosis, PE – Pulmonary embolism, VTE – Venous thromboembolic 










P Value / Odds 
ratio (95% CI) 
P Value / Odds 
ratio (95% CI) 
All patients, N 101 147 19,218   
Mean days (±SD) 200.9±222.1 204.3±200.4 310.8±335.9‡ 0.902 0.000 
Median days (IQR) 115 (98-244) 146 (95-229) 199 (114-370) - - 
      
Initial therapy,      
Unfractionated heparin 5 (5.0%) 9 (6.1%) 983 (5.1%) 0.80 (0.26-2.46) 0.97 (0.39-2.38) 
Low-molecular-weight heparin 79 (78%) 117 (80%) 16,430 (85%)* 0.92 (0.50-1.71) 0.61 (0.38-0.98) 
Mean LMWH dose (IU/kg/day) 173.1±34.1 176.8±46.8 174.8±41.5 0.546 0.713 
DOACs 11 (11%) 12 (8.2%) 620 (3.2%)‡ 1.38 (0.58-3.25) 3.67 (1.95-6.89) 
Thrombolysis 2 (2.0%) 4 (2.7%) 341 (1.8%) 0.72 (0.13-4.02) 1.12 (0.27-4.55) 
No anticoagulation 0 0 16 (0.08%) - 1.000 
Vena cava filter 1 (0.99%) 4 (2.7%) 284 (1.5%) 0.36 (0.04-3.25) 0.67 (0.09-4.80) 
Duration: mean days (SD) 11.8±12.5 11.6±22.7 13.5±43.4 0.934 0.693 
Duration: median days (IQR) 7 (5-15) 7 (4-14) 8 (5-11) - - 
Long-term therapy*,      
VKAs 65 (64%) 96 (65%) 13,721 (71%) 0.96 (0.56-1.63) 0.72 (0.48-1.09) 
LMWH 9 (8.9%) 22 (15%) 2,792 (15%) 0.56 (0.24-1.26) 0.58 (0.29-1.14) 
DOACs 26 (26%) 22 (15%)* 2,208 (11%)‡ 1.97 (1.04-3.72) 2.67 (1.71-4.18) 
Duration: mean days (SD) 173.8±140 215.3±258.5 311.1±340.3‡ 0.105 0.000 
Duration: median days (IQR) 107 (89-233) 139 (92-221) 195 (111-367) - - 
DOAC – Direct oral anticoagulant, LMWH – Low molecular weight heparin, VKA – Vitamin K antagonist 
* Long-term therapy was defined as the later of the following: 1) After 10 days of the VTE; 2) After bridging between UFH or LMWH; 3) 
For DOAC, once loading was complete (e.g. 21 days for rivaroxaban). *p <0.05; ‡p <0.001.   
  
Table 4: Outcomes in Patients Presenting with Post-Knee Arthroscopy and Unprovoked Venous 







Events per 100 
patient-years 
N 
Events per 100 
patient-years 
N 
Events per 100 
patient-years 
Patients, N 101 147 19,218 
Duration of follow-up    
Mean days (±SD) 201±222 204±200 311±336‡ 
Median days (IQR) 115 (98-244) 146 (95-229) 199 (114-370)‡ 
    
Recurrent DVT 1 1.97 (0.10-9.73) 2 2.46 (0.41-8.11) 218 1.35 (1.18-1.54) 
Recurrent PE 0 - 2 2.47 (0.41-8.15) 160 0.99 (0.84-1.15) 
Recurrent VTE 1 1.97 (0.10-9.73) 4 4.98 (1.58-12.0) 373 2.33 (2.11-2.58) 
Major bleeding 0 - 3 3.65 (0.93-9.94) 374 2.31 (2.09-2.56) 
Non-major bleeding 4 7.50 (2.38-18.1) 1 1.23 (0.06-6.06) 660 4.14 (3.84-4.47) 
Death 0 - 6 7.30 (2.96-15.2)* 632 3.87 (3.57-4.18) 
Fatal PE 0 - 0 - 49 0.30 (0.22-0.39) 
Fatal bleeding 0 - 0 - 42 0.26 (0.19-0.34) 
       
*p <0.05; ‡p <0.001.   
Table 5: Outcomes in Patients Presenting with Post-Knee Arthroscopy and Unprovoked Venous 







Events per 100 
patient-years 
N 
Events per 100 
patient-years 
N 
Events per 100 
patient-years 
Patients, N 56 61 6,410 
Duration of follow-up,    
Mean days (±SD) 451±508 348±463 321±383 
Median days (IQR) 231 (95-694) 136 (59-359) 178 (57-438) 
    
Recurrent DVT 2 2.89 (0.49-9.56) 3 5.17 (1.31-14.1) 330 5.91 (5.29-6.57) 
Recurrent PE 2 3.09 (0.52-10.2) 0 - 327 5.87 (5.26-6.53) 
Recurrent VTE 4 6.18 (1.96-14.9) 3 5.17 (1.31-14.1) 657 11.9 (11.0-12.8) 
Major bleeding 0 - 0 - 37 0.66 (0.47-0.90) 
Non-major bleeding 0 - 0 - 44 0.79 (0.58-1.04) 
Death 0 - 2 3.44 (0.58-11.4) 256 4.55 (4.02-5.13) 
Fatal PE 0 - 0 - 4 0.07 (0.02-0.17) 
Fatal bleeding 0 - 0 - 17 0.30 (0.18-0.47) 
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Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of 
post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient 
outcomes have not been described. 
Methods 
Patients from the “Registro Informatizado Enfermedad TromboEmbolica” (RIETE) who had 
confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, 
and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, 
treatment and outcomes including recurrent VTE, bleeds or death were compared. 
Results 
A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE 
were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P<0.0001) and had 
less history of VTE [5.9% vs. 20%, OR 0.26 (0.11-0.59)].  Among patients with isolated DVT, 
there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06-
0.19)]. Treatment duration was shorter in the post-arthroscopy group (174±140 vs. 311±340 
days, P<0.0001) and more often with DOAC [OR 3.67 (1.95-6.89)]. Recurrent VTE occurred in 
6.18 (1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years [HR 0.52 (0.16-1.26)] after 
treatment in the post-arthroscopy and unprovoked groups, respectively. Recurrent VTE 
occurred in 5.17 (1.31-14.1) per 100 patient years in a separate post bone-fracture group (n = 
147), also not statistically different than the post-arthroscopy recurrence rate. 
Conclusions 
After anticoagulation cessation, some patients post-knee arthroscopy develop VTE. While our 
small sample size precludes drawing firm conclusions, this signal should warrant further 
research into the optimal treatment duration for these patients, as some patients may be at 



































































 Treatment patterns for patients with post-arthroscopy VTE differ from those for patients 
with unprovoked VTE 
 Bleeding or thrombotic complications were uncommon during anticoagulation 
 Once anticoagulation is stopped, recurrent VTE occurs in some patients with post-
arthroscopy VTE 
 Future research should be aimed at identifying which patients with post-arthroscopy VTE 




































































Knee arthroscopy is usually an elective procedure, performed in relatively young patients, often 
without thromboprophylaxis1. Importantly, these procedures are common; 4 million knee 
arthroscopies are performed annually, typically in the outpatient setting2, 3. After the procedure 
is done, patients often ambulate on their other leg and are fully ambulatory within a few 
weeks. However, despite short procedural duration and early ambulation, proximal deep vein 
thrombosis (DVT)4, 5 and pulmonary embolism (PE) may occur 6-13 with fatal PE cases reported14-
16.  Risk factors for developing venous thromboembolic events (VTE) after these procedures and 
analysis of prevention methods have been published 1, 5, 17-23.  However, treatment patterns 
have not been systematically reported and data regarding patient outcomes are variable3, 18, 19.  
We therefore sought to describe patient characteristics, treatment patterns and outcomes in 
patients who developed VTE after knee arthroscopy in the “Registro Informatizado Enfermedad 
TromboEmbolica” (RIETE) 24. Furthermore, we compared these to patients who developed 
either provoked, post bone-fracture, or unprovoked VTE within the registry. 
 
Methods: 
RIETE is a multi-center, multi-national, ongoing prospective registry of confirmed acute VTE that 
has been populated since March 2001 24.  RIETE is registered at Clinicaltrials.gov (NCT: 
02832245).  As of June 2017, over 72,000 patients have been enrolled to the registry, from 179 
centers around the world. Importantly, to study the outcomes of patients in real-world practice, 
RIETE does not mandate specific treatment protocols and treatment is at the discretion of 
attending physicians at the participating sites. Only patients with at least 3 months of follow-up 
are included. Data quality is constantly monitored by a contract research organization (CRO). All 
patients provide oral consent to their participation in the registry, according to the 
requirements of the Ethics Committee within each participating hospital. 
As noted, only objectively confirmed VTE (ultrasonography or venography for DVT, pulmonary 


































































Participating centers have local Institutional Review Board approval with patients providing 
informed consent for registry enrollment.   
VTE Groups 
Patients who developed VTE between February 2009 and December 2017 within 60 days of 
knee arthroscopy were compared to: 1) patients with unprovoked VTE; and 2) patients with 
provoked VTE post bone-fracture. Unprovoked VTE were defined as lacking transient risk 
factors including recent immobilization >4 days, recent surgery, estrogen use, pregnancy or 
puerperium, and recent travel. Post bone fracture VTE was defined as occurring within 60 days 
of a fracture. 
Variables 
For each patient, the following information was obtained: demographics, past medical history, 
history of prior thrombosis and known thrombophilia; signs, symptoms and laboratory data at 
presentation; treatment including anticoagulation use and type and whether thrombolysis or 
an inferior vena cava filter were offered; and outcomes during the first 3 months including VTE 
recurrence, bleeding and mortality. 
Outcomes 
Major bleeding was defined as occurring in a critical site (retroperitoneal, spinal, or 
intracranial), bleeding requiring transfusion of 2 or more units of packed red blood cells, or fatal 
bleeding 25.  Fatal PE was defined as any death occurring within 10 days of confirmed PE 
without an alternative explanation.  
Recurrent DVT was defined as a new episode of symptomatic and objectively confirmed 
ipsilateral or contralateral DVT. Proximal DVT was defined as occurring in the popliteal vein or 
in a more proximal vein. 
Statistical analysis  
Mann-Whitney test and Student t-test were used to compare continuous variables, and 


































































confidence intervals (CIs) were calculated, and a two tailed P value of .05 was considered 
statistically significant. All reported analyses were unadjusted due to the lack of clinical 
granularity necessary for true adjustment for confounders in the examined clinical scenarios.  




A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE 
were identified.  
Post-arthroscopy patients were younger (49.5 vs. 66 years, P<0.0001), more often male [68% 
vs. 55%, OR 1.77 (1.16-2.69)] and had less history of DVT or PE [5.9% vs. 20%, OR 0.26 (0.11-
0.59)] compared to patients with unprovoked VTE, respectively (Table 1). Also, post-
arthroscopy patients had a lower incidence of chronic diseases such as diabetes [OR 0.06 (0.01-
0.45)], hypertension [OR 0.32 (0.20-0.50)] and chronic lung disease [OR 0.23 (0.07-0.72)] 
compared to patients with unprovoked VTE.  One average VTE occurred within 22.3±17.1 days 
of surgery; 71% of patients with VTE after arthroscopy had received pharmacologic prophylaxis, 
for an average of 12.1±7.9 days. There was no difference in the rate of known thrombophilia 
between groups (2.0% vs. 3.4%).  
About half of the patients in both groups presented with PE (49% and 57%, for the post-
arthroscopy and unprovoked groups, respectively). Among patients with isolated PE, a minority 
of patients in both groups presented with hypotension (4.1% and 2.4%) or syncope (18% and 
15%). Among patients with isolated DVT, there were fewer proximal DVT in the post-
arthroscopy group [40% vs. 86%, OR 0.11 (0.06-0.19)]. Otherwise, presentation was similar 
between groups (Table 2). 
Nearly all patients in each group were treated with anticoagulation initially.  Treatment 


































































P<0.0001) and more often with direct oral anticoagulants (DOAC) initially [OR 3.67 (1.95-6.89)], 
and at 3 months [OR 2.67 (1.71-4.18)] (Table 3).  
During treatment with anticoagulation, recurrent VTE occurred in 1.97 (0.10-9.73) and 2.33 
(2.11-2.58) per 100 patient years in the post-arthroscopy and unprovoked groups, respectively 
(Table 4). There were no major bleeds in the post-arthroscopy group and there were 2.31 (2.09-
2.56) per 100 patient years in the unprovoked group.  
Follow-up was available for 56 and 6,410 patients, in the post-arthroscopy and unprovoked 
groups, respectively (Table 5). After treatment was stopped, recurrent VTE occurred in 6.18 
(1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years in the post-arthroscopy and in the 
unprovoked groups, respectively HR 0.52 (0.16-1.26). 
Comparison to Patients with Post-Bone Fracture VTE 
There were 147 patients with post bone-fracture VTE. These patients were older (55.4 vs. 49.5 
years, P<0.01), and more were diabetic (6.8% vs. 1%, P<0.05) compared to patients with post-
arthroscopy VTE. Otherwise baseline characteristics and presentation were similar. Treatment 
patterns were also similar, though fewer patients in the post bone-fracture group received 
DOAC (15% vs. 26%, P<0.05). The mean duration of therapy post bone-fracture was 
215.3±258.5 days. During treatment with anticoagulation mortality occurred in 7.3 (2.96-15.2) 
per 100 patient years in the post bone-fracture group, while none of the patient in the post-
arthroscopy group had died (P<0.05). Otherwise, outcomes during treatment with 
anticoagulation and after anticoagulation was stopped were similar between patients in both 
groups. 
Discussion: 
In this first systematic analysis of post knee-arthroscopy VTE, most patients had a benign 
presentation including distal DVT or low-risk PE. Nonetheless, in absolute terms the incidence 
of syncope was still high. Treatment typically included anticoagulation and adverse events 
during treatment were uncommon. While recurrent VTE did occur once anticoagulation was 


































































clearly provoked or unprovoked VTE. However, drawing firm conclusions may not be possible 
given our small sample size.  
Descriptions of post-arthroscopy VTE treatment and outcomes are lacking in the literature. 
Several case-reports have reported fatal PE post knee-arthroscopy15, 16. In a retrospective series 
of 102 patients undergoing knee arthroscopy, 8 developed calf-DVT and at a median of 118 
days 50% had auto-lysed, while 1 had propagated to the popliteal vein1. In the Efficacy of 
Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA) study 120 patients 
undergoing knee-arthroscopy received prophylaxis with rivaroxaban and were compared to 119 
patients who received placebo 19. While the study reported outcomes for all patients, 7 patients 
in the placebo arm developed proximal (n=1) or distal (n=6) DVT while 1 patient in the study 
arm developed distal DVT (P=0.03). Treatment was not reported, however none of the patients 
developed PE or died. Similarly, in the largest study to-date where 1327 patients undergoing 
knee-arthroscopy were randomized to receive low molecular weight heparin or placebo for 
thromboprophylaxis, at 3 months the incidence of VTE was 0.6% in the treatment arm and 0.4% 
in the control arm and while treatment was not detailed, no deaths were noted 3. In contrast, 
the current study included only patients who have already sustained a VTE. We report 
management and outcomes.  In order to provide context, we compared post-arthroscopy VTE 
to two separate cohorts:  those with clearly unprovoked VTE and  those with provoked VTE 
after bone-fracture. On average, treatment was longer than 6 months; more than the typical 
duration of therapy for provoked events26.  While more patients in the post-arthroscopy group 
received a DOAC, it should be noted that this did not reflect differences in availability as most 
patients were recruited over similar timeframes. During the course of anticoagulation, there 
were no differences in the rate of patients who developed VTE recurrences between patients 
with post-arthroscopy and either comparison group.  While firm conclusions cannot be drawn,  
some patients did have recurrent VTE once anticoagulation was stopped. In absolute terms the 
recurrence rate was lower than in the unprovoked group, however not in a statistically 
significant manner. But, recurrent events were also noted in patients with post-fracture VTE. 


































































Strengths of the current study include the detailed description of treatment and outcomes 
during and after anticoagulation. However, our study has limitations. As there were very few 
outcomes in the post-arthroscopy group, we cannot comment about the association of baseline 
characteristics and outcomes.  We could not report on specific procedural data; however 
increased procedural risk was demonstrated across all indications of knee arthroscopy10. 
Finally, we only reported symptomatic events. Proactive surveillance may detect patients with 
asymptomatic DVT1, 4, 19. However, this practice may over-estimate the incidence of DVT3, 5 and 
may result in treatment-related complications14. Furthermore, by reporting only symptomatic 
events our results reflect clinical practice3, 21, 28.  
Conclusions: 
In this largest study to date examining post-knee arthroscopy VTE treatment and outcomes, 
there were few thrombotic complications during anticoagulation. Recurrent VTE did occur in 
some patients after anticoagulation cessation. Our small sample size and low event rate 
preclude drawing strong conclusions, however this signal should warrant further investigation 
into the optimal treatment duration for these patients as long-term prevention may be 










































































P Value / Odds 
ratio (95% CI) 
Arthroscopy vs. 
fracture 
P Value / Odds 
ratio (95% CI) 
Arthroscopy vs. 
unprovoked 
Patients, N 101 147 19,218   
Age  49.5±13.1 55.4±18.8† 66±16.8‡ 0.004 0.000 
Male sex  69 (68%) 79 (54%)* 10,563 (55%)† 1.86 (1.09-3.15) 1.77 (1.16-2.69) 
Body weight(Kg/m2±SD) 27.6±4.8 27.9±4.3 28.7±5.5 0.627 0.083 
BMI 27.6±4.8 27.9±4.3 28.7±5.5 0.627 0.083 
Chronic lung disease  3 (3.0%) 5 (3.4%) 2,270 (12%)† 0.87 (0.20-3.72) 0.23 (0.07-0.72) 
Congestive heart failure  3 (3.0%) 13 (8.8%) 1,258 (6.5%) 0.32 (0.09-1.14) 0.44 (0.14-1.38) 
Diabetes  1 (0.99%) 10 (6.8%)* 2,654 (14%)‡ 0.14 (0.02-1.09) 0.06 (0.01-0.45) 
Hypertension  23 (23%) 40 (27%) 9,268 (48%)‡ 0.79 (0.44-1.42) 0.32 (0.20-0.50) 
Prior myocardial infarction  4 (4.0%) 8 (5.4%) 1,262 (6.6%) 0.72 (0.21-2.45) 0.59 (0.22-1.60) 
Prior ischemic stroke  2 (2.0%) 1 (0.68%) 1,069 (5.6%) 2.95 (0.26-32.97) 0.34 (0.08-1.39) 
Recent major bleeding  0 4 (2.7%) 183 (0.95%) - - 
Active cancer  1 (0.99%) 6 (4.1%) 0 0.24 (0.03-1.98) - 
History of DVT or PE  6 (5.9%) 6 (4.1%) 3,756 (20%)‡ 1.48 (0.46-4.74) 0.26 (0.11-0.59) 
Pregnancy  0 0 0 - - 
Hormone use  6 (5.9%) 7 (4.8%) 0 1.26 (0.41-3.88) - 
Antiphospholipid syndrome  1 (0.99%) 2 (1.4%) 433 (2.3%) 0.73 (0.06-8.10) 0.43 (0.06-3.12) 
Known thrombophilia  2 (2.0%) 1 (0.68%) 645 (3.4%) 2.95 (0.26-32.97) 0.58 (0.14-2.36) 
Thromboprophylaxis  72 (71%) 123 (84%)* 0 0.48 (0.26-0.90) - 
 LMWH 70 (69%) 114 (78%) 0 0.65 (0.37-1.16) - 
 UFH 0 0 0 - 0 
 DOAC 0 0 0 - 0 
 Others 1 (0.99%) 0 0 -  
 Unspecified 1 (0.99%) 0 0 -  
 
Duration (mean days 
±SD) 



































































Duration (median days, 
IQR) 
10 (7-14) 21 (10-30) - - - 
BMI – Body mass index, CI – Confidence interval, DVT – Deep vein thrombosis, PE – Pulmonary embolism. *p <0.05; †p <0.01; ‡p 




































































Table 2: Presenting Signs, Symptoms in Patients Presenting with Post-Knee Arthroscopy and Unprovoked Venous 
Thromboembolism 




P Value / Odds 
ratio (95% CI) 
P Value / Odds 
ratio (95% CI) 
All patients, N 101 147 19,218   
Initial VTE presentation,      
Pulmonary embolism 49 (49%) 83 (56%) 10,959 (57%) 0.73 (0.44-1.21) 0.71 (0.48-1.05) 
In patients with PE 49 83 10,959   
Cough 8 (16%) 14 (17%) 2,422 (22%) 0.96 (0.37-2.49) 0.69 (0.32-1.47) 
Dyspnea 34 (69%) 65 (78%) 8,791 (80%) 0.63 (0.28-1.40) 0.56 (0.30-1.03) 
Chest pain 34 (69%) 60 (72%) 5,168 (47%)† 0.87 (0.40-1.89) 2.54 (1.38-4.67) 
Syncope 9 (18%) 6 (7.2%) 1,606 (15%) 2.89 (0.96-8.69) 1.31 (0.63-2.71) 
Heart rate >110 mm Hg 7 (15%) 27 (34%)* 1,835 (17%) 0.35 (0.14-0.88) 0.86 (0.38-1.92) 
SBP levels <90 mm Hg 2 (4.1%) 0 266 (2.4%) - 1.71 (0.41-7.08) 
Sat O2 levels <90% (N=5,928) 5 (21%) 10 (21%) 1,600 (27%) 0.97 (0.29-3.26) 0.71 (0.26-1.90) 
In patients with only DVT 52 64 8,259   
Swollen limb 47 (90%) 55 (86%) 7,445 (90%) 1.54 (0.48-4.91) 1.03 (0.41-2.59) 
Upper limb 1 (2.5%) 2 (4.9%) 656 (11%) 0.50 (0.04-5.74) 0.20 (0.03-1.44) 
   secondary to catheter 1 (100%) 0 109 (17%) 0.333 0.167 
Lower limb 51 (98%) 62 (97%) 7,679 (95%) 1.65 (0.14-18.67) 2.54 (0.35-18.46) 
   Proximal 20 (40%) 41 (66%)† 6,490 (86%)‡ 0.34 (0.16-0.74) 0.11 (0.06-0.19) 
CI – Confidence interval, DVT – Deep vein thrombosis, PE – Pulmonary embolism, VTE – Venous thromboembolic 











































































P Value / Odds 
ratio (95% CI) 
P Value / Odds 
ratio (95% CI) 
All patients, N 101 147 19,218   
Mean days (±SD) 200.9±222.1 204.3±200.4 310.8±335.9‡ 0.902 0.000 
Median days (IQR) 115 (98-244) 146 (95-229) 199 (114-370) - - 
      
Initial therapy,      
Unfractionated heparin 5 (5.0%) 9 (6.1%) 983 (5.1%) 0.80 (0.26-2.46) 0.97 (0.39-2.38) 
Low-molecular-weight heparin 79 (78%) 117 (80%) 16,430 (85%)* 0.92 (0.50-1.71) 0.61 (0.38-0.98) 
Mean LMWH dose (IU/kg/day) 173.1±34.1 176.8±46.8 174.8±41.5 0.546 0.713 
DOACs 11 (11%) 12 (8.2%) 620 (3.2%)‡ 1.38 (0.58-3.25) 3.67 (1.95-6.89) 
Thrombolysis 2 (2.0%) 4 (2.7%) 341 (1.8%) 0.72 (0.13-4.02) 1.12 (0.27-4.55) 
No anticoagulation 0 0 16 (0.08%) - 1.000 
Vena cava filter 1 (0.99%) 4 (2.7%) 284 (1.5%) 0.36 (0.04-3.25) 0.67 (0.09-4.80) 
Duration: mean days (SD) 11.8±12.5 11.6±22.7 13.5±43.4 0.934 0.693 
Duration: median days (IQR) 7 (5-15) 7 (4-14) 8 (5-11) - - 
Long-term therapy*,      
VKAs 65 (64%) 96 (65%) 13,721 (71%) 0.96 (0.56-1.63) 0.72 (0.48-1.09) 
LMWH 9 (8.9%) 22 (15%) 2,792 (15%) 0.56 (0.24-1.26) 0.58 (0.29-1.14) 
DOACs 26 (26%) 22 (15%)* 2,208 (11%)‡ 1.97 (1.04-3.72) 2.67 (1.71-4.18) 
Duration: mean days (SD) 173.8±140 215.3±258.5 311.1±340.3‡ 0.105 0.000 
Duration: median days (IQR) 107 (89-233) 139 (92-221) 195 (111-367) - - 
DOAC – Direct oral anticoagulant, LMWH – Low molecular weight heparin, VKA – Vitamin K antagonist 
* Long-term therapy was defined as the later of the following: 1) After 10 days of the VTE; 2) After bridging between UFH or LMWH; 3) 



































































Table 4: Outcomes in Patients Presenting with Post-Knee Arthroscopy and Unprovoked Venous 







Events per 100 
patient-years 
N 
Events per 100 
patient-years 
N 
Events per 100 
patient-years 
Patients, N 101 147 19,218 
Duration of follow-up    
Mean days (±SD) 201±222 204±200 311±336‡ 
Median days (IQR) 115 (98-244) 146 (95-229) 199 (114-370)‡ 
    
Recurrent DVT 1 1.97 (0.10-9.73) 2 2.46 (0.41-8.11) 218 1.35 (1.18-1.54) 
Recurrent PE 0 - 2 2.47 (0.41-8.15) 160 0.99 (0.84-1.15) 
Recurrent VTE 1 1.97 (0.10-9.73) 4 4.98 (1.58-12.0) 373 2.33 (2.11-2.58) 
Major bleeding 0 - 3 3.65 (0.93-9.94) 374 2.31 (2.09-2.56) 
Non-major bleeding 4 7.50 (2.38-18.1) 1 1.23 (0.06-6.06) 660 4.14 (3.84-4.47) 
Death 0 - 6 7.30 (2.96-15.2)* 632 3.87 (3.57-4.18) 
Fatal PE 0 - 0 - 49 0.30 (0.22-0.39) 
Fatal bleeding 0 - 0 - 42 0.26 (0.19-0.34) 
       
*p <0.05; ‡p <0.001.   
Table 5: Outcomes in Patients Presenting with Post-Knee Arthroscopy and Unprovoked Venous 







Events per 100 
patient-years 
N 
Events per 100 
patient-years 
N 
Events per 100 
patient-years 
Patients, N 56 61 6,410 
Duration of follow-up,    
Mean days (±SD) 451±508 348±463 321±383 
Median days (IQR) 231 (95-694) 136 (59-359) 178 (57-438) 


































































Recurrent DVT 2 2.89 (0.49-9.56) 3 5.17 (1.31-14.1) 330 5.91 (5.29-6.57) 
Recurrent PE 2 3.09 (0.52-10.2) 0 - 327 5.87 (5.26-6.53) 
Recurrent VTE 4 6.18 (1.96-14.9) 3 5.17 (1.31-14.1) 657 11.9 (11.0-12.8) 
Major bleeding 0 - 0 - 37 0.66 (0.47-0.90) 
Non-major bleeding 0 - 0 - 44 0.79 (0.58-1.04) 
Death 0 - 2 3.44 (0.58-11.4) 256 4.55 (4.02-5.13) 
Fatal PE 0 - 0 - 4 0.07 (0.02-0.17) 
Fatal bleeding 0 - 0 - 17 0.30 (0.18-0.47) 
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